Intermittent Administration of Human Parathyroid Hormone(1–34) Prevents Immobilization-Related Bone Loss by Regulating Bone Marrow Capacity for Bone Cells in ddY Mice

Maintaining bone mass by bisphosphonate

Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1-34) administration in ovariectomized rats

✍ Yuichi Takano; Tatsuhiko Tanizawa; Tasuku Mashiba; Naoto Endo; Saburo Nishida; H 📂 Article 📅 2009 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 791 KB

Intermittent treatment with human parathyroid hormone (1-34) ] stimulates bone formation and increases cancellous bone mass in ovariectomized (OW) rats. But PTH-induced cancellous bone rapidly disappears upon cessation of treatment. The fate of cortical bone treated by PTH has not been well characte